1783 related articles for article (PubMed ID: 33555604)
1. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
4. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.
Mado H; Kubicka-Bączyk K; Adamczyk-Sowa M
J Int Med Res; 2021 Sep; 49(9):3000605211044378. PubMed ID: 34528472
[TBL] [Abstract][Full Text] [Related]
5. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
6. [Current state of vaccination against SARS-CoV-2].
Iking-Konert C; Specker C; Krüger K; Schulze-Koops H; Aries P
Z Rheumatol; 2021 Mar; 80(2):158-164. PubMed ID: 33528655
[TBL] [Abstract][Full Text] [Related]
7. [Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology].
Sinagra G; Porcari A; Merlo M; Barillà F; Basso C; Ciccone MM; Curcio A; Mancone M; Mercuro G; Muscoli S; Nodari S; Pedrinelli R; Spaccarotella C; Filardi PP; Indolfi C
G Ital Cardiol (Rome); 2021 Nov; 22(11):894-899. PubMed ID: 34709228
[TBL] [Abstract][Full Text] [Related]
8. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
[TBL] [Abstract][Full Text] [Related]
10. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
Chagla Z
Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
[TBL] [Abstract][Full Text] [Related]
13. Single Dose of an mRNA Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) Vaccine Is Associated With Lower Nasopharyngeal Viral Load Among Nursing Home Residents With Asymptomatic Coronavirus Disease 2019 (COVID-19).
McEllistrem MC; Clancy CJ; Buehrle DJ; Lucas A; Decker BK
Clin Infect Dis; 2021 Sep; 73(6):e1365-e1367. PubMed ID: 33768222
[TBL] [Abstract][Full Text] [Related]
14. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
Wallace M; Woodworth KR; Gargano JW; Scobie HM; Blain AE; Moulia D; Chamberland M; Reisman N; Hadler SC; MacNeil JR; Campos-Outcalt D; Morgan RL; Daley MF; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):749-752. PubMed ID: 34014913
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain.
Del Cura-Bilbao A; López-Mendoza H; Chaure-Pardos A; Vergara-Ugarriza A; Guimbao-Bescós J
Emerg Infect Dis; 2022 Mar; 28(3):591-598. PubMed ID: 35195514
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021.
Yi S; Choe YJ; Kim J; Kim YY; Kim RK; Jang EJ; Lim DS; Byeon HR; Lee S; Park E; Kim SJ; Park YJ
Emerg Infect Dis; 2022 Mar; 28(3):753-756. PubMed ID: 35202529
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccines in patients with SLE.
Tang W; Askanase AD; Khalili L; Merrill JT
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33685998
[TBL] [Abstract][Full Text] [Related]
18. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
[TBL] [Abstract][Full Text] [Related]
20. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
